AustralieFrV1, PubMed, Checkpoint, bibRecord, 002E75

CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.

Identifieur interne : 002E75 ( PubMed/Checkpoint ); précédent : 002E74; suivant : 002E76

CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.

Auteurs : C. Paget [France] ; M T Chow [Australie] ; N A Gherardin [Australie] ; P A Beavis [Australie] ; A P Uldrich [Australie] ; H. Duret [Australie] ; M. Hassane [France] ; F. Souza-Fonseca-Guimaraes [Australie] ; D A Mogilenko [France] ; D. Staumont-Sallé [France] ; N K Escalante [Canada] ; G R Hill [Australie] ; P. Neeson [Australie] ; D S Ritchie [Australie] ; D. Dombrowicz [France] ; T. Mallevaey [Canada] ; F. Trottein [France] ; G T Belz [Australie] ; D I Godfrey [Australie] ; M J Smyth [Australie]

Source :

Immunology and cell biology [ 1440-1711 ] ; 2015.

RBID : pubmed:25385067

Descripteurs français

English descriptors

KwdEn :
- Amino Acid Sequence, Aminoquinolines (pharmacology), Animals, Antigens, CD3 (chemistry), Antigens, CD3 (metabolism), Carrier Proteins (metabolism), Germ Cells (drug effects), Homeostasis (drug effects), Immunity, Inflammasomes (drug effects), Inflammasomes (metabolism), Interleukin-17 (biosynthesis), Interleukin-1beta (metabolism), Interleukin-23, Lung (drug effects), Lung (immunology), Lymphocyte Subsets (drug effects), Lymphocyte Subsets (immunology), Male, Mice, Inbred C57BL, Molecular Sequence Data, NLR Family, Pyrin Domain-Containing 3 Protein, Nuclear Receptor Subfamily 1, Group F, Member 3 (metabolism), Phenotype, Receptors, Antigen, T-Cell, gamma-delta (metabolism), Skin (drug effects), Skin (immunology), T-Lymphocytes (drug effects), T-Lymphocytes (immunology).
MESH :
- chemical , biosynthesis : Interleukin-17.
- chemical , chemistry : Antigens, CD3.
- chemical , drug effects : Inflammasomes.
- chemical , metabolism : Antigens, CD3, Carrier Proteins, Inflammasomes, Interleukin-1beta, Nuclear Receptor Subfamily 1, Group F, Member 3, Receptors, Antigen, T-Cell, gamma-delta.
- chemical , pharmacology : Aminoquinolines.
- drug effects : Germ Cells, Homeostasis, Lung, Lymphocyte Subsets, Skin, T-Lymphocytes.
- immunology : Lung, Lymphocyte Subsets, Skin, T-Lymphocytes.
- Amino Acid Sequence, Animals, Immunity, Interleukin-23, Male, Mice, Inbred C57BL, Molecular Sequence Data, NLR Family, Pyrin Domain-Containing 3 Protein, Phenotype.

Abstract

Interleukin-17A (IL-17A) is a pro-inflammatory cytokine that has an important role at mucosal sites in a wide range of immune responses including infection, allergy and auto-immunity. γδ T cells are recognized as IL-17 producers, but based on the level of CD3 expression, we now define the remarkable ability of a CD3(bright) γδ T-cell subset with an effector memory phenotype to rapidly produce IL-17A, but not interferon-γ. CD3(bright) γδ T cells uniformly express the canonical germline encoded Vγ6/Vδ1(+) T-cell receptor. They are widely distributed with a preferential representation in the lungs and skin are negatively impacted in the absence of retinoic acid receptor-related orphan receptor gammat expression or endogenous flora. This population responded rapidly to various stimuli in a mechanism involving IL-23 and NOD-like receptor family, pyrin domain containing 3 (NLRP3)-inflammasome-dependent IL-1β. Finally, we demonstrated that IL-17-producing CD3(bright) γδ T cells responded promptly and strongly to pneumococcal infection and during skin inflammation. Here, we propose a new way to specifically analyze IL-17-producing Vγ6/Vδ1(+) T cells based on the level of CD3 signals. Using this gating strategy, our data reinforce the crucial role of this γδ T-cell subset in respiratory and skin disorders.

DOI: 10.1038/icb.2014.94
PubMed: 25385067

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 003030
to stream PubMed, to step Curation: 002F49

Links to Exploration step

pubmed:25385067

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.</title>
<author><name sortKey="Paget, C" sort="Paget, C" uniqKey="Paget C" first="C" last="Paget">C. Paget</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [4] University of Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [4] University of Lille 2, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
<settlement type="city">Melbourne</settlement>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Chow, M T" sort="Chow, M T" uniqKey="Chow M" first="M T" last="Chow">M T Chow</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gherardin, N A" sort="Gherardin, N A" uniqKey="Gherardin N" first="N A" last="Gherardin">N A Gherardin</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Beavis, P A" sort="Beavis, P A" uniqKey="Beavis P" first="P A" last="Beavis">P A Beavis</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Uldrich, A P" sort="Uldrich, A P" uniqKey="Uldrich A" first="A P" last="Uldrich">A P Uldrich</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Duret, H" sort="Duret, H" uniqKey="Duret H" first="H" last="Duret">H. Duret</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hassane, M" sort="Hassane, M" uniqKey="Hassane M" first="M" last="Hassane">M. Hassane</name>
<affiliation wicri:level="3"><nlm:affiliation>1] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [2] University of Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>1] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [2] University of Lille 2, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Souza Fonseca Guimaraes, F" sort="Souza Fonseca Guimaraes, F" uniqKey="Souza Fonseca Guimaraes F" first="F" last="Souza-Fonseca-Guimaraes">F. Souza-Fonseca-Guimaraes</name>
<affiliation wicri:level="1"><nlm:affiliation>QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mogilenko, D A" sort="Mogilenko, D A" uniqKey="Mogilenko D" first="D A" last="Mogilenko">D A Mogilenko</name>
<affiliation wicri:level="3"><nlm:affiliation>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Staumont Salle, D" sort="Staumont Salle, D" uniqKey="Staumont Salle D" first="D" last="Staumont-Sallé">D. Staumont-Sallé</name>
<affiliation wicri:level="3"><nlm:affiliation>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille, France [4] Department of Dermatology, Claude Huriez Hospital, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille, France [4] Department of Dermatology, Claude Huriez Hospital, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Escalante, N K" sort="Escalante, N K" uniqKey="Escalante N" first="N K" last="Escalante">N K Escalante</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Immunology, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Immunology, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hill, G R" sort="Hill, G R" uniqKey="Hill G" first="G R" last="Hill">G R Hill</name>
<affiliation wicri:level="1"><nlm:affiliation>1] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia [2] Department of Bone Marrow Transplantation, Royal Brisbane Hospital, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia [2] Department of Bone Marrow Transplantation, Royal Brisbane Hospital, Herston, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Neeson, P" sort="Neeson, P" uniqKey="Neeson P" first="P" last="Neeson">P. Neeson</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ritchie, D S" sort="Ritchie, D S" uniqKey="Ritchie D" first="D S" last="Ritchie">D S Ritchie</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dombrowicz, D" sort="Dombrowicz, D" uniqKey="Dombrowicz D" first="D" last="Dombrowicz">D. Dombrowicz</name>
<affiliation wicri:level="3"><nlm:affiliation>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mallevaey, T" sort="Mallevaey, T" uniqKey="Mallevaey T" first="T" last="Mallevaey">T. Mallevaey</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Immunology, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Immunology, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Trottein, F" sort="Trottein, F" uniqKey="Trottein F" first="F" last="Trottein">F. Trottein</name>
<affiliation wicri:level="3"><nlm:affiliation>1] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [2] University of Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>1] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [2] University of Lille 2, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Belz, G T" sort="Belz, G T" uniqKey="Belz G" first="G T" last="Belz">G T Belz</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Godfrey, D I" sort="Godfrey, D I" uniqKey="Godfrey D" first="D I" last="Godfrey">D I Godfrey</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia [2] Australian Research Council Centre of Excellence in Advanced Medical Imaging at University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia [2] Australian Research Council Centre of Excellence in Advanced Medical Imaging at University of Melbourne, Parkville, Victoria</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smyth, M J" sort="Smyth, M J" uniqKey="Smyth M" first="M J" last="Smyth">M J Smyth</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia [4] School of Medicine, University of Queensland, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia [4] School of Medicine, University of Queensland, Herston, Queensland</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25385067</idno>
<idno type="pmid">25385067</idno>
<idno type="doi">10.1038/icb.2014.94</idno>
<idno type="wicri:Area/PubMed/Corpus">003030</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003030</idno>
<idno type="wicri:Area/PubMed/Curation">002F49</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002F49</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F49</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002F49</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.</title>
<author><name sortKey="Paget, C" sort="Paget, C" uniqKey="Paget C" first="C" last="Paget">C. Paget</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [4] University of Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [4] University of Lille 2, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
<settlement type="city">Melbourne</settlement>
</placeName>
<orgName type="university">Université de Melbourne</orgName>
</affiliation>
</author>
<author><name sortKey="Chow, M T" sort="Chow, M T" uniqKey="Chow M" first="M T" last="Chow">M T Chow</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gherardin, N A" sort="Gherardin, N A" uniqKey="Gherardin N" first="N A" last="Gherardin">N A Gherardin</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Beavis, P A" sort="Beavis, P A" uniqKey="Beavis P" first="P A" last="Beavis">P A Beavis</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Uldrich, A P" sort="Uldrich, A P" uniqKey="Uldrich A" first="A P" last="Uldrich">A P Uldrich</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Duret, H" sort="Duret, H" uniqKey="Duret H" first="H" last="Duret">H. Duret</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hassane, M" sort="Hassane, M" uniqKey="Hassane M" first="M" last="Hassane">M. Hassane</name>
<affiliation wicri:level="3"><nlm:affiliation>1] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [2] University of Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>1] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [2] University of Lille 2, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Souza Fonseca Guimaraes, F" sort="Souza Fonseca Guimaraes, F" uniqKey="Souza Fonseca Guimaraes F" first="F" last="Souza-Fonseca-Guimaraes">F. Souza-Fonseca-Guimaraes</name>
<affiliation wicri:level="1"><nlm:affiliation>QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mogilenko, D A" sort="Mogilenko, D A" uniqKey="Mogilenko D" first="D A" last="Mogilenko">D A Mogilenko</name>
<affiliation wicri:level="3"><nlm:affiliation>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Staumont Salle, D" sort="Staumont Salle, D" uniqKey="Staumont Salle D" first="D" last="Staumont-Sallé">D. Staumont-Sallé</name>
<affiliation wicri:level="3"><nlm:affiliation>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille, France [4] Department of Dermatology, Claude Huriez Hospital, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille, France [4] Department of Dermatology, Claude Huriez Hospital, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Escalante, N K" sort="Escalante, N K" uniqKey="Escalante N" first="N K" last="Escalante">N K Escalante</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Immunology, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Immunology, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hill, G R" sort="Hill, G R" uniqKey="Hill G" first="G R" last="Hill">G R Hill</name>
<affiliation wicri:level="1"><nlm:affiliation>1] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia [2] Department of Bone Marrow Transplantation, Royal Brisbane Hospital, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia [2] Department of Bone Marrow Transplantation, Royal Brisbane Hospital, Herston, Queensland</wicri:regionArea>
<wicri:noRegion>Queensland</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Neeson, P" sort="Neeson, P" uniqKey="Neeson P" first="P" last="Neeson">P. Neeson</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ritchie, D S" sort="Ritchie, D S" uniqKey="Ritchie D" first="D S" last="Ritchie">D S Ritchie</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dombrowicz, D" sort="Dombrowicz, D" uniqKey="Dombrowicz D" first="D" last="Dombrowicz">D. Dombrowicz</name>
<affiliation wicri:level="3"><nlm:affiliation>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mallevaey, T" sort="Mallevaey, T" uniqKey="Mallevaey T" first="T" last="Mallevaey">T. Mallevaey</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Immunology, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Immunology, University of Toronto, Toronto, Ontario</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Trottein, F" sort="Trottein, F" uniqKey="Trottein F" first="F" last="Trottein">F. Trottein</name>
<affiliation wicri:level="3"><nlm:affiliation>1] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [2] University of Lille 2, Lille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>1] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [2] University of Lille 2, Lille</wicri:regionArea>
<placeName><region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Belz, G T" sort="Belz, G T" uniqKey="Belz G" first="G T" last="Belz">G T Belz</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria</wicri:regionArea>
<wicri:noRegion>Victoria</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Godfrey, D I" sort="Godfrey, D I" uniqKey="Godfrey D" first="D I" last="Godfrey">D I Godfrey</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia [2] Australian Research Council Centre of Excellence in Advanced Medical Imaging at University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia [2] Australian Research Council Centre of Excellence in Advanced Medical Imaging at University of Melbourne, Parkville, Victoria</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smyth, M J" sort="Smyth, M J" uniqKey="Smyth M" first="M J" last="Smyth">M J Smyth</name>
<affiliation wicri:level="4"><nlm:affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia [4] School of Medicine, University of Queensland, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia [4] School of Medicine, University of Queensland, Herston, Queensland</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Immunology and cell biology</title>
<idno type="eISSN">1440-1711</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Aminoquinolines (pharmacology)</term>
<term>Animals</term>
<term>Antigens, CD3 (chemistry)</term>
<term>Antigens, CD3 (metabolism)</term>
<term>Carrier Proteins (metabolism)</term>
<term>Germ Cells (drug effects)</term>
<term>Homeostasis (drug effects)</term>
<term>Immunity</term>
<term>Inflammasomes (drug effects)</term>
<term>Inflammasomes (metabolism)</term>
<term>Interleukin-17 (biosynthesis)</term>
<term>Interleukin-1beta (metabolism)</term>
<term>Interleukin-23</term>
<term>Lung (drug effects)</term>
<term>Lung (immunology)</term>
<term>Lymphocyte Subsets (drug effects)</term>
<term>Lymphocyte Subsets (immunology)</term>
<term>Male</term>
<term>Mice, Inbred C57BL</term>
<term>Molecular Sequence Data</term>
<term>NLR Family, Pyrin Domain-Containing 3 Protein</term>
<term>Nuclear Receptor Subfamily 1, Group F, Member 3 (metabolism)</term>
<term>Phenotype</term>
<term>Receptors, Antigen, T-Cell, gamma-delta (metabolism)</term>
<term>Skin (drug effects)</term>
<term>Skin (immunology)</term>
<term>T-Lymphocytes (drug effects)</term>
<term>T-Lymphocytes (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Aminoquinoléines (pharmacologie)</term>
<term>Animaux</term>
<term>Antigènes CD3 ()</term>
<term>Antigènes CD3 (métabolisme)</term>
<term>Cellules germinales ()</term>
<term>Données de séquences moléculaires</term>
<term>Homéostasie ()</term>
<term>Immunité</term>
<term>Inflammasomes ()</term>
<term>Inflammasomes (métabolisme)</term>
<term>Interleukine-1 bêta (métabolisme)</term>
<term>Interleukine-17 (biosynthèse)</term>
<term>Interleukine-23</term>
<term>Lymphocytes T ()</term>
<term>Lymphocytes T (immunologie)</term>
<term>Membre-3 du groupe F de la sous-famille-1 de récepteurs nucléaires (métabolisme)</term>
<term>Mâle</term>
<term>Peau ()</term>
<term>Peau (immunologie)</term>
<term>Phénotype</term>
<term>Poumon ()</term>
<term>Poumon (immunologie)</term>
<term>Protéine-3 de la famille des NLR contenant un domaine pyrine</term>
<term>Protéines de transport (métabolisme)</term>
<term>Récepteur lymphocytaire T antigène, gamma-delta (métabolisme)</term>
<term>Souris de lignée C57BL</term>
<term>Sous-populations de lymphocytes ()</term>
<term>Sous-populations de lymphocytes (immunologie)</term>
<term>Séquence d'acides aminés</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Interleukin-17</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antigens, CD3</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Inflammasomes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antigens, CD3</term>
<term>Carrier Proteins</term>
<term>Inflammasomes</term>
<term>Interleukin-1beta</term>
<term>Nuclear Receptor Subfamily 1, Group F, Member 3</term>
<term>Receptors, Antigen, T-Cell, gamma-delta</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Aminoquinolines</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Interleukine-17</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Germ Cells</term>
<term>Homeostasis</term>
<term>Lung</term>
<term>Lymphocyte Subsets</term>
<term>Skin</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Lymphocytes T</term>
<term>Peau</term>
<term>Poumon</term>
<term>Sous-populations de lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Lung</term>
<term>Lymphocyte Subsets</term>
<term>Skin</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antigènes CD3</term>
<term>Inflammasomes</term>
<term>Interleukine-1 bêta</term>
<term>Membre-3 du groupe F de la sous-famille-1 de récepteurs nucléaires</term>
<term>Protéines de transport</term>
<term>Récepteur lymphocytaire T antigène, gamma-delta</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Aminoquinoléines</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Animals</term>
<term>Immunity</term>
<term>Interleukin-23</term>
<term>Male</term>
<term>Mice, Inbred C57BL</term>
<term>Molecular Sequence Data</term>
<term>NLR Family, Pyrin Domain-Containing 3 Protein</term>
<term>Phenotype</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Antigènes CD3</term>
<term>Cellules germinales</term>
<term>Données de séquences moléculaires</term>
<term>Homéostasie</term>
<term>Immunité</term>
<term>Inflammasomes</term>
<term>Interleukine-23</term>
<term>Lymphocytes T</term>
<term>Mâle</term>
<term>Peau</term>
<term>Phénotype</term>
<term>Poumon</term>
<term>Protéine-3 de la famille des NLR contenant un domaine pyrine</term>
<term>Souris de lignée C57BL</term>
<term>Sous-populations de lymphocytes</term>
<term>Séquence d'acides aminés</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Interleukin-17A (IL-17A) is a pro-inflammatory cytokine that has an important role at mucosal sites in a wide range of immune responses including infection, allergy and auto-immunity. γδ T cells are recognized as IL-17 producers, but based on the level of CD3 expression, we now define the remarkable ability of a CD3(bright) γδ T-cell subset with an effector memory phenotype to rapidly produce IL-17A, but not interferon-γ. CD3(bright) γδ T cells uniformly express the canonical germline encoded Vγ6/Vδ1(+) T-cell receptor. They are widely distributed with a preferential representation in the lungs and skin are negatively impacted in the absence of retinoic acid receptor-related orphan receptor gammat expression or endogenous flora. This population responded rapidly to various stimuli in a mechanism involving IL-23 and NOD-like receptor family, pyrin domain containing 3 (NLRP3)-inflammasome-dependent IL-1β. Finally, we demonstrated that IL-17-producing CD3(bright) γδ T cells responded promptly and strongly to pneumococcal infection and during skin inflammation. Here, we propose a new way to specifically analyze IL-17-producing Vγ6/Vδ1(+) T cells based on the level of CD3 signals. Using this gating strategy, our data reinforce the crucial role of this γδ T-cell subset in respiratory and skin disorders.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25385067</PMID>
<DateCreated><Year>2015</Year>
<Month>02</Month>
<Day>10</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>12</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>11</Month>
<Day>16</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1711</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>93</Volume>
<Issue>2</Issue>
<PubDate><Year>2015</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Immunology and cell biology</Title>
<ISOAbbreviation>Immunol. Cell Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.</ArticleTitle>
<Pagination><MedlinePgn>198-212</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/icb.2014.94</ELocationID>
<Abstract><AbstractText>Interleukin-17A (IL-17A) is a pro-inflammatory cytokine that has an important role at mucosal sites in a wide range of immune responses including infection, allergy and auto-immunity. γδ T cells are recognized as IL-17 producers, but based on the level of CD3 expression, we now define the remarkable ability of a CD3(bright) γδ T-cell subset with an effector memory phenotype to rapidly produce IL-17A, but not interferon-γ. CD3(bright) γδ T cells uniformly express the canonical germline encoded Vγ6/Vδ1(+) T-cell receptor. They are widely distributed with a preferential representation in the lungs and skin are negatively impacted in the absence of retinoic acid receptor-related orphan receptor gammat expression or endogenous flora. This population responded rapidly to various stimuli in a mechanism involving IL-23 and NOD-like receptor family, pyrin domain containing 3 (NLRP3)-inflammasome-dependent IL-1β. Finally, we demonstrated that IL-17-producing CD3(bright) γδ T cells responded promptly and strongly to pneumococcal infection and during skin inflammation. Here, we propose a new way to specifically analyze IL-17-producing Vγ6/Vδ1(+) T cells based on the level of CD3 signals. Using this gating strategy, our data reinforce the crucial role of this γδ T-cell subset in respiratory and skin disorders.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paget</LastName>
<ForeName>C</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [4] University of Lille 2, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chow</LastName>
<ForeName>M T</ForeName>
<Initials>MT</Initials>
<AffiliationInfo><Affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gherardin</LastName>
<ForeName>N A</ForeName>
<Initials>NA</Initials>
<AffiliationInfo><Affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Beavis</LastName>
<ForeName>P A</ForeName>
<Initials>PA</Initials>
<AffiliationInfo><Affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Uldrich</LastName>
<ForeName>A P</ForeName>
<Initials>AP</Initials>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Duret</LastName>
<ForeName>H</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hassane</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>1] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [2] University of Lille 2, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Souza-Fonseca-Guimaraes</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mogilenko</LastName>
<ForeName>D A</ForeName>
<Initials>DA</Initials>
<AffiliationInfo><Affiliation>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Staumont-Sallé</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille, France [4] Department of Dermatology, Claude Huriez Hospital, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Escalante</LastName>
<ForeName>N K</ForeName>
<Initials>NK</Initials>
<AffiliationInfo><Affiliation>Department of Immunology, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hill</LastName>
<ForeName>G R</ForeName>
<Initials>GR</Initials>
<AffiliationInfo><Affiliation>1] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia [2] Department of Bone Marrow Transplantation, Royal Brisbane Hospital, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Neeson</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ritchie</LastName>
<ForeName>D S</ForeName>
<Initials>DS</Initials>
<AffiliationInfo><Affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dombrowicz</LastName>
<ForeName>D</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>1] University of Lille 2, Lille, France [2] INSERM U1011, Institut Pasteur de Lille, Lille, France [3] European Genomic Institute of Diabetes, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mallevaey</LastName>
<ForeName>T</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Immunology, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Trottein</LastName>
<ForeName>F</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>1] INSERM U1019, Centre d'Infection et d'Immunité de Lille, Institut Pasteur de Lille, Lille, France [2] University of Lille 2, Lille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Belz</LastName>
<ForeName>G T</ForeName>
<Initials>GT</Initials>
<AffiliationInfo><Affiliation>Division of Molecular Immunology, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Godfrey</LastName>
<ForeName>D I</ForeName>
<Initials>DI</Initials>
<AffiliationInfo><Affiliation>1] Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Victoria, Australia [2] Australian Research Council Centre of Excellence in Advanced Medical Imaging at University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Smyth</LastName>
<ForeName>M J</ForeName>
<Initials>MJ</Initials>
<AffiliationInfo><Affiliation>1] Peter MacCallum Cancer Centre, Cancer Immunology Program, St Andrews Place, East Melbourne, Victoria, Australia [2] Sir Peter MacCallum Department of Oncology and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia [3] QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia [4] School of Medicine, University of Queensland, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>11</Month>
<Day>11</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Immunol Cell Biol</MedlineTA>
<NlmUniqueID>8706300</NlmUniqueID>
<ISSNLinking>0818-9641</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000634">Aminoquinolines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017252">Antigens, CD3</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053583">Interleukin-1beta</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D053759">Interleukin-23</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C492716">Nlrp3 protein, mouse</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057132">Nuclear Receptor Subfamily 1, Group F, Member 3</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016692">Receptors, Antigen, T-Cell, gamma-delta</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C000589613">T-cell receptor Vgamma6, mouse</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>P1QW714R7M</RegistryNumber>
<NameOfSubstance UI="C056493">imiquimod</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 2012 Jan;1247:34-45</RefSource>
<PMID Version="1">22239719</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1995 Apr 15;154(8):3814-20</RefSource>
<PMID Version="1">7706721</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 1988 Feb 18;331(6157):627-31</RefSource>
<PMID Version="1">2963227</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4942-7</RefSource>
<PMID Version="1">15037737</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2006 Oct 1;177(7):4662-9</RefSource>
<PMID Version="1">16982905</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Vaccine. 2010 Jul 12;28(31):5068-74</RefSource>
<PMID Version="1">20478344</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2011 Mar 14;208(3):491-503</RefSource>
<PMID Version="1">21383056</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nucleic Acids Res. 1998 Jan 1;26(1):297-303</RefSource>
<PMID Version="1">9399859</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2010 Jul;10(7):479-89</RefSource>
<PMID Version="1">20559326</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Immunol. 2008 Jun;9(6):641-9</RefSource>
<PMID Version="1">18454151</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell. 2006 Sep 22;126(6):1121-33</RefSource>
<PMID Version="1">16990136</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunity. 2009 Aug 21;31(2):331-41</RefSource>
<PMID Version="1">19682929</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Immunol. 2012 Sep;42(9):2221-31</RefSource>
<PMID Version="1">22949320</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Immunol. 2009 Dec;39(12):3488-97</RefSource>
<PMID Version="1">19830744</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Immunol. 2005 Apr;35(4):1292-300</RefSource>
<PMID Version="1">15770699</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Exp Immunol. 2009 Sep;157(3):385-94</RefSource>
<PMID Version="1">19664147</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2010 May;120(5):1762-73</RefSource>
<PMID Version="1">20364087</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2009 Jun 15;182(12):7348-51</RefSource>
<PMID Version="1">19494256</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2009 Jun 25;113(26):6611-8</RefSource>
<PMID Version="1">19395673</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunity. 2007 Oct;27(4):597-609</RefSource>
<PMID Version="1">17950005</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2013 Oct;123(10):4364-74</RefSource>
<PMID Version="1">24051381</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunology. 2008 Oct;125(2):170-7</RefSource>
<PMID Version="1">18397272</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Leukoc Biol. 2004 Jan;75(1):68-75</RefSource>
<PMID Version="1">14525969</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Immunol. 2010 Sep;40(9):2391-400</RefSource>
<PMID Version="1">20690180</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunity. 2004 Oct;21(4):467-76</RefSource>
<PMID Version="1">15485625</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunity. 2009 Aug 21;31(2):181-3</RefSource>
<PMID Version="1">19699169</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunol Lett. 2009 Dec 2;127(1):8-12</RefSource>
<PMID Version="1">19682496</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Jul 7;118(1):129-38</RefSource>
<PMID Version="1">21505189</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>EMBO J. 1993 Dec;12(12):4863-75</RefSource>
<PMID Version="1">8223495</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2009 May 15;182(10):6540-9</RefSource>
<PMID Version="1">19414809</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Semin Immunol. 2009 Apr;21(2):84-91</RefSource>
<PMID Version="1">19298946</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Infect Immun. 2011 Nov;79(11):4503-10</RefSource>
<PMID Version="1">21875963</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunity. 2013 Jul 25;39(1):184-95</RefSource>
<PMID Version="1">23890071</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell Mol Immunol. 2008 Jun;5(3):203-8</RefSource>
<PMID Version="1">18582402</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Immunol. 2009 May;39(5):1231-40</RefSource>
<PMID Version="1">19350552</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17549-54</RefSource>
<PMID Version="1">23047700</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 1986 Aug 28-Sep 3;322(6082):836-40</RefSource>
<PMID Version="1">2943999</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2007 May 14;204(5):995-1001</RefSource>
<PMID Version="1">17470641</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2011 May 15;186(10 ):5738-48</RefSource>
<PMID Version="1">21471445</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trends Immunol. 2012 Sep;33(9):459-66</RefSource>
<PMID Version="1">22677185</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2007 Apr 1;178(7):4466-72</RefSource>
<PMID Version="1">17372004</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunity. 2012 Jul 27;37(1):48-59</RefSource>
<PMID Version="1">22770884</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2010 Apr 15;184(8):4055-61</RefSource>
<PMID Version="1">20368285</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunity. 2010 Nov 24;33(5):736-51</RefSource>
<PMID Version="1">21093318</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunity. 2009 Aug 21;31(2):321-30</RefSource>
<PMID Version="1">19682928</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 1992 Jan 1;175(1):203-9</RefSource>
<PMID Version="1">1530959</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunity. 2011 Jul 22;35(1):59-68</RefSource>
<PMID Version="1">21737317</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Jul 21;118(3):586-93</RefSource>
<PMID Version="1">21606479</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Immunol. 2009 Apr;10(4):427-36</RefSource>
<PMID Version="1">19270712</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2012 Apr 15;188(8):3928-39</RefSource>
<PMID Version="1">22412194</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell Immunol. 2008 Jan;251(1):50-5</RefSource>
<PMID Version="1">18423430</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2011 Jun 12;17(7):837-44</RefSource>
<PMID Version="1">21666695</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Allergy Clin Immunol. 2009 May;123(5):986-94; quiz 995-6</RefSource>
<PMID Version="1">19410688</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 1990 Feb 22;343(6260):754-7</RefSource>
<PMID Version="1">2154700</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2009 May 15;182(10):6435-43</RefSource>
<PMID Version="1">19414797</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunity. 2011 Oct 28;35(4):596-610</RefSource>
<PMID Version="1">21982596</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2014 Apr 1;192(7):2975-83</RefSource>
<PMID Version="1">24600030</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cytokine Growth Factor Rev. 2010 Dec;21(6):443-8</RefSource>
<PMID Version="1">21095154</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2009 May 1;182(9):5836-45</RefSource>
<PMID Version="1">19380832</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2012 Sep 1;206(5):723-34</RefSource>
<PMID Version="1">22723642</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunol Cell Biol. 2011 Aug;89(6):739-46</RefSource>
<PMID Version="1">21263463</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arthritis Rheum. 2012 May;64(5):1420-9</RefSource>
<PMID Version="1">22144400</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2010 Jul;10(7):467-78</RefSource>
<PMID Version="1">20539306</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell Host Microbe. 2010 Feb 18;7(2):140-50</RefSource>
<PMID Version="1">20159619</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Semin Immunol. 2010 Aug;22(4):193-8</RefSource>
<PMID Version="1">20451408</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2009 Oct 1;183(7):4169-75</RefSource>
<PMID Version="1">19767566</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000634" MajorTopicYN="N">Aminoquinolines</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017252" MajorTopicYN="N">Antigens, CD3</DescriptorName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005854" MajorTopicYN="N">Germ Cells</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006706" MajorTopicYN="N">Homeostasis</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007109" MajorTopicYN="N">Immunity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053583" MajorTopicYN="N">Interleukin-1beta</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053759" MajorTopicYN="N">Interleukin-23</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016131" MajorTopicYN="N">Lymphocyte Subsets</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057132" MajorTopicYN="N">Nuclear Receptor Subfamily 1, Group F, Member 3</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016692" MajorTopicYN="N">Receptors, Antigen, T-Cell, gamma-delta</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>07</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2014</Year>
<Month>09</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2014</Year>
<Month>09</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>11</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25385067</ArticleId>
<ArticleId IdType="pii">icb201494</ArticleId>
<ArticleId IdType="doi">10.1038/icb.2014.94</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
<li>Canada</li>
<li>France</li>
</country>
<region><li>Hauts-de-France</li>
<li>Nord-Pas-de-Calais</li>
<li>Ontario</li>
<li>Victoria (État)</li>
</region>
<settlement><li>Lille</li>
<li>Melbourne</li>
<li>Toronto</li>
</settlement>
<orgName><li>Université de Melbourne</li>
<li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="France"><region name="Hauts-de-France"><name sortKey="Paget, C" sort="Paget, C" uniqKey="Paget C" first="C" last="Paget">C. Paget</name>
</region>
<name sortKey="Dombrowicz, D" sort="Dombrowicz, D" uniqKey="Dombrowicz D" first="D" last="Dombrowicz">D. Dombrowicz</name>
<name sortKey="Hassane, M" sort="Hassane, M" uniqKey="Hassane M" first="M" last="Hassane">M. Hassane</name>
<name sortKey="Mogilenko, D A" sort="Mogilenko, D A" uniqKey="Mogilenko D" first="D A" last="Mogilenko">D A Mogilenko</name>
<name sortKey="Staumont Salle, D" sort="Staumont Salle, D" uniqKey="Staumont Salle D" first="D" last="Staumont-Sallé">D. Staumont-Sallé</name>
<name sortKey="Trottein, F" sort="Trottein, F" uniqKey="Trottein F" first="F" last="Trottein">F. Trottein</name>
</country>
<country name="Australie"><region name="Victoria (État)"><name sortKey="Chow, M T" sort="Chow, M T" uniqKey="Chow M" first="M T" last="Chow">M T Chow</name>
</region>
<name sortKey="Beavis, P A" sort="Beavis, P A" uniqKey="Beavis P" first="P A" last="Beavis">P A Beavis</name>
<name sortKey="Belz, G T" sort="Belz, G T" uniqKey="Belz G" first="G T" last="Belz">G T Belz</name>
<name sortKey="Duret, H" sort="Duret, H" uniqKey="Duret H" first="H" last="Duret">H. Duret</name>
<name sortKey="Gherardin, N A" sort="Gherardin, N A" uniqKey="Gherardin N" first="N A" last="Gherardin">N A Gherardin</name>
<name sortKey="Godfrey, D I" sort="Godfrey, D I" uniqKey="Godfrey D" first="D I" last="Godfrey">D I Godfrey</name>
<name sortKey="Hill, G R" sort="Hill, G R" uniqKey="Hill G" first="G R" last="Hill">G R Hill</name>
<name sortKey="Neeson, P" sort="Neeson, P" uniqKey="Neeson P" first="P" last="Neeson">P. Neeson</name>
<name sortKey="Ritchie, D S" sort="Ritchie, D S" uniqKey="Ritchie D" first="D S" last="Ritchie">D S Ritchie</name>
<name sortKey="Smyth, M J" sort="Smyth, M J" uniqKey="Smyth M" first="M J" last="Smyth">M J Smyth</name>
<name sortKey="Souza Fonseca Guimaraes, F" sort="Souza Fonseca Guimaraes, F" uniqKey="Souza Fonseca Guimaraes F" first="F" last="Souza-Fonseca-Guimaraes">F. Souza-Fonseca-Guimaraes</name>
<name sortKey="Uldrich, A P" sort="Uldrich, A P" uniqKey="Uldrich A" first="A P" last="Uldrich">A P Uldrich</name>
</country>
<country name="Canada"><region name="Ontario"><name sortKey="Escalante, N K" sort="Escalante, N K" uniqKey="Escalante N" first="N K" last="Escalante">N K Escalante</name>
</region>
<name sortKey="Mallevaey, T" sort="Mallevaey, T" uniqKey="Mallevaey T" first="T" last="Mallevaey">T. Mallevaey</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E75 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002E75 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:25385067
   |texte=   CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:25385067" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.

CD3bright signals on γδ T cells identify IL-17A-producing Vγ6Vδ1+ T cells.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki